Replies to post #195483 on Biotech Values

[DewDiligence]

ESPR—And +30% up today.

The sell-off was unusually severe for a biotech company that hasn’t failed a clinical trial or been involved in some kind of scandal. I thought about buying some, but didn’t; there are a lot of other compelling buys around.